Aadi Competitors

Delisted . USA . 
Stock . Aadi Bioscience
AADIDelisted Stock  USD 2.05  0.10  4.65%   
Aadi Bioscience competes with Anebulo Pharmaceuticals, Adagene, Acrivon Therapeutics,, AnaptysBio, and Mineralys Therapeutics,; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Aadi Bioscience competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Aadi Bioscience to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Aadi Bioscience Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Aadi Bioscience competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Aadi Bioscience's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.102.066.65
Details
Intrinsic
Valuation
LowRealHigh
0.101.956.54
Details
Naive
Forecast
LowNextHigh
0.042.106.69
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1.762.112.46
Details

Aadi Bioscience Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Aadi Bioscience and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Aadi and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Aadi Bioscience does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
ANTX
+ 0.82
MLYS
GLUE
+ 0.56
ACRV
AVTE
+ 0.55
ACRV
AVTE
+ 0.52
ANTX
ANTX
+ 0.45
ANEB
AVTE
+ 0.42
ANEB
  
High negative correlations   
ADAG
- 0.53
ANEB
AVTE
- 0.44
ANAB
ANAB
- 0.31
ACRV
ANTX
- 0.24
ANAB
GLUE
- 0.2
ANAB
MLYS
- 0.18
ADAG

Risk-Adjusted Indicators

There is a big difference between Aadi Stock performing well and Aadi Bioscience Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Aadi Bioscience's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
ANEB  5.70  0.55  0.09  0.39  5.55 
(8.40)
 19.58 
(10.43)
 48.29 
ADAG  2.63 (0.32) 0.00  0.45  0.00 
 0.00 
 4.62 
(7.34)
 18.68 
ACRV  4.20 (0.30) 0.00 (0.13) 0.00 
 0.00 
 10.17 
(8.24)
 30.57 
ANAB  4.34  0.39  0.08  0.24  4.38 
(5.50)
 9.84 
(7.48)
 43.41 
MLYS  4.36  0.68  0.14 (0.35) 4.26 
(5.13)
 10.04 
(8.23)
 50.53 
ANTX  2.36  0.21  0.08 (2.05) 2.30 
(2.99)
 5.41 
(3.85)
 17.09 
AVTE  1.31 (0.03) 0.00 (0.06) 0.00 
 0.00 
 2.07 
(3.27)
 10.45 
GRCL  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
THRX  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
GLUE  3.58 (0.35) 0.00 (0.27) 0.00 
 0.00 
 7.34 
(7.69)
 30.08 
All Fundamental Data

Aadi Bioscience Competitive Analysis

The better you understand Aadi Bioscience competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Aadi Bioscience's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Aadi Bioscience's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
AADI ANEB ADAG ACRV ANAB MLYS ANTX AVTE GLUE DSGN
 4.65 
 2.05 
Aadi
 1.31 
 1.55 
Anebulo
 2.44 
 1.68 
Adagene
 51.58 
 2.61 
Acrivon
 1.36 
 18.19 
AnaptysBio
 3.75 
 16.15 
Mineralys
 0.66 
 1.52 
AN2
 1.57 
 2.51 
Aerovate
 3.17 
 5.49 
Monte
 9.59 
 4.15 
Design
Market Volatility
(90 Days Market Risk)
Dangerous
Dangerous
Relatively risky
Moderately volatile
Somewhat reliable
Somewhat reliable
Risky
Moderately volatile
Slightly risky
Unstable
Market Performance
(90 Days Performance)
Very Weak
Weak
Very Weak
Very Weak
OK
OK
Modest
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Low
Very High
Low
Low
Low
Above Average
Average
Below Average
Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Fairly Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Buy
Strong Buy
Strong Buy
Strong Buy
Hold
Hold
Strong Buy
Buy
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Cautious Hold
Strong Sell
Strong Sell
Cautious Hold
Strong Sell
Sell
Hold
Strong Sell
Sell
Current Ratio
9.87
30.4
3.1
N/A
22.79
N/A
28.17
40.85
20.11
48.96
Net Asset
132.42 M
4.07 M
89.27 M
138.26 M
483.83 M
205.9 M
138.74 M
80.33 M
438.73 M
252.09 M
Profit Margin
-2.46
N/A
N/A
N/A
-1.59
N/A
N/A
N/A
-0.96
N/A
EBITDA
(65.36 M)
(8.05 M)
(36.13 M)
(59.85 M)
(92.74 M)
(192.4 M)
4.9 M
(74.31 M)
(81.11 M)
(62.38 M)
Operating Margin
-1.49
N/A
-45.35
N/A
-0.22
N/A
N/A
N/A
0.21
N/A
Current Valuation
35.53 M
47.86 M
11.66 M
(8.77 M)
196.16 M
817.27 M
(50.43 M)
(15.44 M)
29.17 M
36.7 M
Price To Book
1.41
4.2
1.55
0.89
7.98
5.31
0.51
0.9
1.61
1.16
Retained Earnings
(268.96 M)
(65.4 M)
(311.18 M)
(116.42 M)
(759.33 M)
(302.52 M)
(154.46 M)
(233.05 M)
(438.59 M)
(227.21 M)
Current Asset
N/A
N/A
N/A
N/A
297.84 M
N/A
N/A
N/A
N/A
N/A
Beta
0.34
-1.01
0.58
0.86
0.025
1.51
0.14
1.0
1.5
1.78
Number Of Employees
53
2
174
58
136
51
41
30
134
54
Shares Outstanding
46.29 M
25.93 M
44.27 M
31.14 M
30.67 M
62.8 M
29.88 M
28.98 M
61.51 M
56.76 M
Cash Flow From Operations
(59.66 M)
(8.09 M)
(29.7 M)
(42.64 M)
(135.34 M)
(166.31 M)
(53.29 M)
(71.2 M)
42 M
(43.1 M)
Total Debt
1.27 M
260.58 K
17.79 M
4.64 M
16.04 M
14.65 M
14.04 M
417 K
42.72 M
1.53 M
Return On Equity
-0.66
-1.14
-0.46
-0.46
-1.83
-0.82
-0.54
-0.75
-0.36
-0.19
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.35
-0.66
-0.2
-0.29
-0.15
-0.53
-0.32
-0.45
-0.14
-0.14
Number Of Shares Shorted
764.36 K
66.89 K
40.12 K
1.13 M
9.31 M
1.75 M
78.58 K
4.12 M
8.03 M
3.14 M
Book Value Per Share
2.8
0.15
1.28
6.33
2.33
3.84
2.94
2.64
3.63
4.27
Current Liabilities
N/A
N/A
N/A
N/A
16.6 M
N/A
N/A
N/A
N/A
N/A
Total Asset
132.42 M
4.07 M
89.27 M
138.26 M
483.83 M
205.9 M
138.74 M
80.33 M
438.73 M
252.09 M
Debt To Equity
0.016
N/A
0.15
N/A
0.066
N/A
N/A
0.008
0.16
0.011
Short Ratio
8.87
1.94
0.33
19.11
6.91
5.94
0.75
32.29
17.6
23.66
Target Price
3.0
6.0
10.54
21.57
37.64
38.29
2.67
2.33
16.13
7.33
Shares Owned By Institutions
50.02
28.18
25.54
74.97
95.6
87.07
46.3
99.99
99.3
59.33
Market Capitalization
97.21 M
42.79 M
108.46 M
167.82 M
573.78 M
1.05 B
44.82 M
73.91 M
358.6 M
279.84 M
Price To Earning
N/A
N/A
N/A
N/A
81.21
N/A
3.96
0.64
1.91
N/A
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Price To Sales
3.88
N/A
96.06
N/A
6.29
N/A
N/A
N/A
4.74
22642.01
Net Income
(65.77 M)
(8.2 M)
(33.42 M)
(60.39 M)
(145.23 M)
(177.81 M)
(64.73 M)
(69.63 M)
(72.7 M)
(49.59 M)
Earnings Per Share
-2.28
-0.32
-0.72
-2.66
-5.12
-3.66
-1.99
-2.99
-0.98
-0.88
Shares Owned By Insiders
6.09
64.22
10.65
22.06
4.4
2.0
22.5
0.01
0.7
36.35
Revenue
24.35 M
N/A
103.2 K
N/A
91.28 M
N/A
N/A
N/A
75.62 M
N/A
Working Capital
98.19 M
3.25 M
49.59 M
116.39 M
386.45 M
190.71 M
96.46 M
106.59 M
220.49 M
239.58 M
Cash And Equivalents
118.74 M
14.55 M
168.04 M
N/A
442.15 M
N/A
113.39 M
151.99 M
294.14 M
359.38 M
Cash Per Share
5.65
0.62
3.87
N/A
15.66
N/A
5.84
6.22
6.32
6.45
Gross Profit
(27.54 M)
N/A
10.18 M
N/A
(72.56 M)
N/A
N/A
N/A
(37.24 M)
(44.35 M)
Day Typical Price
2.09
1.59
1.72
3.18
18.08
16.43
1.48
2.51
5.61
4.26
Accumulation Distribution
0.0776
1181.4
614.13
806050.0
49203.13
97134.63
33200.71
N/A
65666.45
7351.76
Market Facilitation Index
0.17
0.0
0.0
0.0
0.0
0.0
0.0
N/A
0.0
0.0
Daily Balance Of Power
(0.59)
0.0952
0.2105
(1.46)
(0.29)
(0.50)
0.0556
(9,223,372,036,855)
(0.32)
(0.85)
Period Momentum Indicator
(0.10)
0.02
0.04
(2.78)
(0.25)
(0.63)
0.01
(0.04)
(0.18)
(0.44)
Rate Of Daily Change
0.95
1.01
1.02
0.48
0.99
0.96
1.01
0.98
0.97
0.9
Day Median Price
2.11
1.61
1.74
3.47
18.03
16.58
1.46
2.51
5.67
4.32
Price Action Indicator
(0.11)
(0.04)
(0.04)
(2.24)
0.035
(0.74)
0.065
(0.02)
(0.27)
(0.39)
Relative Strength Index
33.2
55.17
50.83
46.51
55.02
62.19
67.77
52.24
57.58
50.99
Coefficient Of Variation
82399.9
1498.77
(1,082)
(1,972)
1581.39
1035.27
1425.55
(11,642)
(1,419)
(1,838)
Mean Deviation
4.08
5.7
2.63
4.2
4.34
4.36
2.36
1.31
3.58
4.19
Jensen Alpha
(0)
0.5454
(0.32)
(0.30)
0.3932
0.6844
0.2056
(0.03)
(0.35)
(0.32)
Total Risk Alpha
(0.03)
0.5213
(0.34)
(0.31)
0.3763
0.6552
0.1951
(0.03)
(0.37)
(0.34)
Sortino Ratio
(0.0007)
0.0902
N/A
N/A
0.0846
0.1395
0.0777
N/A
N/A
N/A
Downside Variance
30.11
36.69
N/A
N/A
21.82
23.51
6.8
N/A
N/A
N/A
Standard Deviation
7.45
8.38
3.41
5.64
6.45
7.13
3.07
1.74
4.82
5.67
Kurtosis
22.53
3.34
0.8069
1.59
7.13
17.09
1.79
2.4
1.93
1.12
Potential Upside
6.76
19.58
4.62
10.17
9.84
10.04
5.41
2.07
7.34
8.72
Treynor Ratio
(0)
0.3935
0.446
(0.13)
0.2419
(0.35)
(2.05)
(0.06)
(0.27)
(0.29)
Maximum Drawdown
62.23
48.29
18.68
30.57
43.41
50.53
17.09
10.45
30.08
24.91
Variance
55.55
70.26
11.66
31.83
41.58
50.87
9.43
3.04
23.23
32.2
Market Risk Adjusted Performance
0.0057
0.4035
0.456
(0.12)
0.2519
(0.34)
(2.04)
(0.05)
(0.26)
(0.28)
Risk Adjusted Performance
0.0099
0.0653
(0.07)
(0.03)
0.0621
0.0903
0.0665
(0)
(0.05)
(0.04)
Skewness
3.43
1.4
(0.51)
0.7512
1.83
2.98
0.962
0.5162
(0.48)
0.3337
Semi Deviation
5.12
5.55
N/A
N/A
4.38
4.26
2.3
N/A
N/A
N/A
Information Ratio
(0.0005)
0.0652
(0.1)
(0.05)
0.0612
0.0948
0.066
(0.02)
(0.07)
(0.06)
Value At Risk
(8.96)
(10.43)
(7.34)
(8.24)
(7.48)
(8.23)
(3.85)
(3.27)
(7.69)
(9.07)
Expected Short fall
(5.18)
(8.40)
N/A
N/A
(5.50)
(5.13)
(2.99)
N/A
N/A
N/A
Downside Deviation
5.49
6.06
N/A
N/A
4.67
4.85
2.61
N/A
N/A
N/A
Semi Variance
26.24
30.75
N/A
N/A
19.16
18.14
5.3
N/A
N/A
N/A

Aadi Bioscience Competition Performance Charts

JavaScript chart by amCharts 3.21.152025FebMarFeb 14Feb 19Feb 24MarMar 06Mar 11Mar 16Mar 21Mar 26-20%0%20%40% Show all
JavaScript chart by amCharts 3.21.15Aadi Bioscience Anebulo Pharmaceuticals Adagene Acrivon Therapeutics, AnaptysBio Mineralys Therapeutics, AN2 Therapeutics Aerovate Therapeutics Dow Jones Industrial

Five steps to successful analysis of Aadi Bioscience Competition

Aadi Bioscience's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Aadi Bioscience in relation to its competition. Aadi Bioscience's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Aadi Bioscience in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Aadi Bioscience's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Aadi Bioscience, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Aadi Bioscience position

In addition to having Aadi Bioscience in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Restaurants Thematic Idea Now

Restaurants
Restaurants Theme
Entities that are involved in restaurant business, as well as coffee shop chains and other eateries. The Restaurants theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Restaurants Theme or any other thematic opportunities.
View All  Next Launch
Check out Aadi Bioscience Correlation with its peers.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Other Consideration for investing in Aadi Stock

If you are still planning to invest in Aadi Bioscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aadi Bioscience's history and understand the potential risks before investing.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.

Discover investing ideas

Utilize additional investing modules

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY